Abstract
Background: Reliable circulating biomarkers reflecting tumor-related immune-inflammatory activation are of increasing interest in clinical biochemistry. Triggering receptor expressed on myeloid cells-1 (TREM-1) is a key amplifier of myeloid-driven inflammatory signaling, and its soluble form (sTREM-1) can be detected in peripheral blood. However, the clinical and biochemical relevance of circulating sTREM-1 in breast cancer remains insufficiently characterized.
Methods: This single-center observational study included 132 patients with treatment-naive stage I–III breast cancer, 68 patients with benign breast disease, and 60 healthy controls. Serum sTREM-1 levels were measured in fasting blood samples, together with conventional biochemical and hematological parameters, including C-reactive protein (CRP), carbohydrate antigen 15-3 (CA15-3), carcinoembryonic antigen (CEA), and derived inflammatory indices (NLR, PLR, LMR, and SII). Associations between sTREM-1 and clinicopathological features, systemic inflammatory markers, and disease-free survival (DFS) were analyzed. Diagnostic performance was evaluated using receiver operating characteristic (ROC) analysis, and prognostic value was assessed using Kaplan–Meier curves and Cox regression models.
Results: Serum sTREM-1 levels were significantly elevated in patients with breast cancer compared with both benign disease and healthy controls (P<0.001). Higher sTREM-1 concentrations were associated with increased tumor burden, lymph node involvement, advanced stage, and elevated Ki-67 expression (all P<0.05). Correlation analysis demonstrated that sTREM-1 was positively associated with CRP, NLR, PLR, and SII, and inversely associated with LMR (all P<0.001), indicating a close link with systemic inflammatory activation. For differentiating breast cancer from benign breast disease, sTREM-1 showed good diagnostic performance (AUC=0.842), which further improved in combination with CA15-3 and NLR (AUC=0.889). During follow-up, elevated sTREM-1 levels were associated with significantly reduced DFS, and multivariate analysis confirmed sTREM-1 as an independent prognostic factor (HR=1.96, 95% CI: 1.01–3.80, P=0.046).
Conclusions: Circulating sTREM-1 is significantly increased in breast cancer and reflects myeloid-driven immune-inflammatory activation. As a measurable serum biomarker, sTREM-1 provides clinically relevant information for both auxiliary diagnosis and prognosis evaluation. These findings support its potential application in clinical biochemistry as a noninvasive indicator of tumor-associated inflammatory responses.
Keywords
Array
Array
Array
Array
Array
References
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.